Haleos Labs Limited (NSE:HALEOSLABS)

India · Delayed Price · Currency is INR

1,423.10

+16.90 (1.20%)

Jun 15, 2026, 3:29 PM IST

22.72% (1Y)

Market Cap	4.30B +4.6%
Revenue (ttm)	3.34B -3.2%
Net Income	173.12M -13.9%
EPS	57.26 -13.9%
Shares Out	3.02M
PE Ratio	24.85
Forward PE	n/a
Dividend	1.50 (0.11%)
Ex-Dividend Date	Sep 24, 2025

Volume	581
Open	1,499.90
Previous Close	1,406.20
Day's Range	1,395.10 - 1,499.90
52-Week Range	1,067.00 - 1,774.00
Beta	0.34
Analysts	Strong Buy
Price Target	n/a
Earnings Date	May 29, 2026

About Haleos Labs

Haleos Labs Limited engages in the manufacturing of active pharmaceutical ingredients (API) and intermediates in India. The company offers API and intermediates in areas, such as anti-ulcer, anti-migraine, anti-hypertensive, erectile dysfunction, anti-cancer, antifungal, anti-obesity, anti-emetic, anti-depressant, anti-worm, anti-infective, anti-gout, anti-convulsant, antiviral, and anesthesia, as well as antihistamine, diuretics, hair loss, and ophthalmic API products. It also exports its products. The company was formerly known as SMS Lifesci... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1990

Employees 592

Stock Exchange National Stock Exchange of India

Ticker Symbol HALEOSLABS

Full Company Profile

Financial Performance

In fiscal year 2026, Haleos Labs's revenue was 3.34 billion, a decrease of -3.17% compared to the previous year's 3.45 billion. Earnings were 173.12 million, a decrease of -13.91%.

Financial Statements